Last reviewed · How we verify
NCT05605145: PCP
PCP in Immunocompromised Population in Southern China
trial testing PCR was used to detect pneumocystis in respiratory specimens in Immunocompromised Patients in 300 participants. Status unknown.
31 December 2022
Quick facts
| Lead sponsor | First Affiliated Hospital of Guangxi Medical University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 12 May 2021 |
| Primary completion | 31 December 2022 |
| Estimated completion | 30 June 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- PCR was used to detect pneumocystis in respiratory specimens
Conditions studied
- Immunocompromised Patients — all drugs for Immunocompromised Patients →
- Pneumocystis Pneumonia — all drugs for Pneumocystis Pneumonia →
- Diagnosis — all drugs for Diagnosis →
- Polymerase Chain Reaction — all drugs for Polymerase Chain Reaction →
Sponsor
First Affiliated Hospital of Guangxi Medical University
Who can join
Eligibility, any sex, with Immunocompromised Patients or Pneumocystis Pneumonia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the sensitivity and specificity of the combined detection system for the diagnosis of pneumocystis infection in immunocompromised population in Southern China.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05605145
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Immunocompromised Patients
Currently open trials in the same condition.
- NCT07295535 — Analysis of the Specificity and Persistence of Nasal Immune Responses to Respiratory Viral Antigens in Immunocompromised · recruiting
- NCT05597761 — Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC) · active not recruiting
Other First Affiliated Hospital of Guangxi Medical University trials
Trials by the same sponsor.
- NCT07459296 — Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC · Phase 3 · recruiting
- NCT07342322 — A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatial · Phase 2 · not yet recruiting
- NCT07338357 — Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML · EARLY_PHASE1 · not yet recruiting
- NCT07132008 — Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer · Phase 3 · not yet recruiting
- NCT07074444 — Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05605145 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Guangxi Medical University
- Last refreshed: 4 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05605145.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing